Gene patents: a crowded IP field

Since the end of the first era of genome sequencing with the conclusion of the human genome project, the challenge facing the life sciences industry has been to apply our understanding to practical applications.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.

Regulation & Industry

G 1/25: EPO settles controversial patent description question

4 September 2026 Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

More features

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

The UPC plugs another gap in its procedural rulebook

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Abbott IP chief: ‘Firms without AI policies scare me’

Emotional Perception: What next for patent holders?

Rooted in rights: Lessons from plant patent infringement and invalidity cases

Gene patents: a crowded IP field

More on this story

Editor's picks

Editor's picks

More features